CCTV+
10.12.2020 10:32:09 CET | Business Wire | Press release
A statement on strengthening media cooperation issued by China Media Group (CMG) and its European media partners, calling on the Chinese and European media to fulfill their responsibilities as public information disseminators and jointly help the international community to gather a strong force to overcome the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005312/en/
CMG and its European media partners issued the statement. /CCTV+
The statement was made during the “2020 European Media Partners Cooperation Online Forum” on December 10, hosted by CMG with the theme of “Mutual Trust Dialogue for Win-Win Cooperation”.
Twenty-eight delegates from 25 organizations in 16 European countries and China had in-depth discussions on how to strengthen coordination, deepen ties, unite to fight the pandemic, and bring greater confidence to the world through in-depth exchanges.
CMG’s President and Editor-in-Chief, Shen Haixiong put forward three proposals on the current media situation. He said, “First, we should deepen cooperation in reporting COVID-19 responses; Second, we should promote the exchange of personnel between the media organizations; Third, we should strengthen the construction of our cooperation mechanism.”
In his speech, he pointed out, China and Europe share a broad consensus and common interests in supporting and practicing multilateralism, strengthening the global response to COVID-19, and jointly promoting global economic recovery and addressing the issue of climate change. We share far more consensus than divergences. Chinese and European media partners will also move towards a new stage of closer, deeper, and more pragmatic dialogue, exchange and cooperation.
Michael Friedenberg, the President of Reuters, said, “We must recognize the power of partnerships in this new media ecosystem. This can take the form of collaborative journalism, industry coalitions, new commercial business opportunities, content-sharing or shared platforms.”
He also mentioned CMG and CCTV+ are important partners and our partnership continues to be a priority.
“Without a clear two-way information communication, there will never be full trust and in-depth cooperation. Therefore, in a friendly relation between different countries and peoples, the media plays a vital role,” said Paolo Panerai, the Editor-in-Chief & CEO of Class Editori S.p.A.’s.
“As global interdependence grows, I believe that media companies cannot work in silos anymore,” Michael Peters, CEO and President of Executive Board of Euronews emphasized. He believes that Euronews and CMG will continue to deepen our collaboration in fostering a better understanding between our cultures.
A launch ceremony of China Business Video (CBV) was also held between CCTV+ and Reuters. It provides Reuters’ customers with financial news content from China, which will be distributed straight by CMG to improve media cooperation between China and other media and to strengthen information exchanges.
At the forum, Teng Yunping, President of CCTV Video News Agency (CCTV+), and Adrian Wells, Managing Director of European News Exchange (ENEX) signed a Strategic Memorandum of Understanding , which signals the official launch of the “European Media Partners (EMP)”. In the future, the two sides will strengthen cooperation on news materials, news reports, overseas reporters, news products, and media forums.
At the same time, the program, BizToday , was released to provide “European Media Partners” with tailored Chinese and European financial news jointly created by CMG, CCTV+ and ENEX.
During the forum, representatives from China and Europe joined an online panel discussion with the theme “Multilateral Cooperation and Mutual Trust, Common Challenges and Win-Win Future” to discuss how the Chinese and European media promote mutual trust between people from both sides and carry out multilateral cooperation to achieve win-win results.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005312/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom